Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inpatient Volume Expansion in Children With STEC to Prevent HUS
NCT03275792Phase 1Withdrawn
- Sponsor
- University of Calgary
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dextrose + sodium chloride in Shiga toxin-producing Escherichia coli infection (STEC) (2 arms), sponsored by University of Calgary. Primary endpoint: Number of children enrolled in the study protocol at 24 months. Planned start May 2020; status: withdrawn.
02
Drugs
dextrose + sodium chloride
03
Conditions
Shiga toxin-producing Escherichia coli infection (STEC)
Beyond the preview
Go deeper on NCT03275792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275792.